InAADR

Drug Information

Drug Name: Arsenic trioxide (1327-53-3)
PubChem ID:
SMILES: O=[As]O[As]=O
InchiKey: IKWTVSLWAPBBKU-UHFFFAOYSA-N
Therapeutic Category: Antineoplastic Agents

Computed Drug Properties

Molecular Weight (dalton): 197.841
LogP: -1.0676
Ring Count: 0
Hydrogen Bond Acceptor Count: 3
Hydrogen Bond Donor Count: 0
Total Polar Surface Area: 43.37

This panel provides information on interacting drugs and their ADRs along with references

Interacting drug Toxicity Interaction Type Mechanism Reference

This panel provides drug-protein interaction and their ADRs along with references

Toxicity Interacting Protein Mechanism Reference
Anemia HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Anemia Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Anemia wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Apoptosis BAX protein (Q07815) Arsenic trioxide-induced death of neuroblastoma cells involves activation of BAX and does not require p53@SO activation of Bax is an important event in As(2)O(3)-induced cell death. [ ADR Type 2 ] Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53
Cardiovascular Disease HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Cardiovascular Disease Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Cardiovascular Disease wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Cytotoxicity Caspase-3 (P42574) As(2)O(3) also caused an INCREASE of cytoplasmic cytochrome c@ translocation of antiapoptosis-inducing factor to the nuclei@ and a slight ACTIVATION of caspase 3@suggesting activation of a cytotoxic pathway different from that induced by conventional chemotherapeutic agents. [ ADR Type 2 ] Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53
Developmental Abnormalities HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Developmental Abnormalities Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Developmental Abnormalities wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Diabetes HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Diabetes Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Diabetes wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Eosinophilia HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Eosinophilia Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Eosinophilia wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Fibrosis Of Kidney HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Fibrosis Of Kidney Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Fibrosis Of Kidney wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Fibrosis Of Liver HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Fibrosis Of Liver Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Fibrosis Of Liver wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Hearing Loss HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Hearing Loss Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Hearing Loss wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Leukopenia HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Leukopenia Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Leukopenia wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Neurologic And Neurobehavioral Disorder HMTIIA (P00023) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Neurologic And Neurobehavioral Disorder Proto-oncogene protein c-fos (P01100) The CAT-Tox (L) assay showed statistically significant inductions(p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)
Neurologic And Neurobehavioral Disorder wild-type p53 (P04637) The p53 protein was expressed in arsenic trioxide-treated cells, however, the densitometric analysis did not show any significant differences (p [ ADR Type 2 ] Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2)

This panel provides drug-food interactions and their ADRs along with references

Food Toxicity Reference

This panel provides information on metabolites and their ADRs along with references

Metabolite Toxicity Place of Metabolism Mechanism Reference

This panel provides information on drug category

Toxicity Source
Abdominal Distension ADReCS
Abdominal Mass MetaADEDB
Abdominal Pain ADReCS
Abdominal Tenderness ADReCS
Abnormal Ecg MetaADEDB
Abnormal Laboratory Findings MetaADEDB
Abnormal Movements MetaADEDB
Abscess Oral MetaADEDB
Accelerated Idioventricular Rhythm MetaADEDB
Acidosis ADReCS
Acute Brain Syndrome MetaADEDB
Acute Promyelocytic Leukaemia Differentiation Syndrome MetaADEDB
Acute Respiratory Distress Syndrome SIDER
Adynamic Ileus MetaADEDB
Aeromona Infection MetaADEDB
Afib MetaADEDB
Agitation ADReCS
Alanine Aminotransferase Increased ADReCS
Alkalosis Hypochloraemic MetaADEDB
Altered State Of Consciousness MetaADEDB
Alveolar Osteitis MetaADEDB
Alveolitis MetaADEDB
Anaemia ADReCS
Anaesthesia MetaADEDB
Anaphylactoid Reaction ADReCS
Angiopathy ADReCS
Anorexia ADReCS
Anxiety ADReCS
Aortic Aneurysm SIDER
Aortic Dissection SIDER
Aortic Regurgitation MetaADEDB
Arrhythmia ADReCS
Arrhythmia Supraventricular ADReCS
Arterial Pressure Nos Decreased MetaADEDB
Arteriospasm Coronary MetaADEDB
Arthralgia ADReCS
Aspartate Aminotransferase Abnormal ADReCS
Aspartate Aminotransferase Increase MetaADEDB
Aspartate Aminotransferase Increased ADReCS
Asthenia ADReCS
Atelectasis MetaADEDB
Atrial Arrhythmia SIDER
Atrial Ectopic Beats MetaADEDB
Atrial Flutter MetaADEDB
Atrial Tachycardia MetaADEDB
Atrioventricular Block First Degree MetaADEDB
Av Dissociation MetaADEDB
Back Ache MetaADEDB
Back Pain ADReCS
Bacterial Infection ADReCS
Basophilia MetaADEDB
Black Stools MetaADEDB
Blindness Transient MetaADEDB
Blister ADReCS
Blood Albumin Decreased MetaADEDB
Blood Alkaline Phosphatase Increased MetaADEDB
Blood Arsenic Increased MetaADEDB
Blood Bicarbonate Decreased MetaADEDB
Blood Bilirubin Increased MetaADEDB
Blood Calcium MetaADEDB
Blood Cholesterol Decreased MetaADEDB
Blood Creatine Phosphokinase Decreased MetaADEDB
Blood Disorder SIDER
Blood Fibrinogen MetaADEDB
Blood Lactate Dehydrogenase Decreased MetaADEDB
Blood Lactate Dehydrogenase Increased MetaADEDB
Blood Magnesium Decreased MetaADEDB
Blood Magnesium Increased MetaADEDB
Blood Ph Increased MetaADEDB
Blood Potassium Decreased MetaADEDB
Blood Pressure Diastolic Decreased MetaADEDB
Blood Pressure Systolic Decreased MetaADEDB
Blood Sodium MetaADEDB
Blood Urea Increased MetaADEDB
Blood Uric Acid MetaADEDB
Blurred Vision MetaADEDB
Body Temperature MetaADEDB
Body Temperature Increased ADReCS
Bone Disorder ADReCS
Bone Inflammation MetaADEDB
Bone Marrow Failure MetaADEDB
Bone Marrow Necrosis MetaADEDB
Bone Pain ADReCS
Brain Herniation MetaADEDB
Brain Oedema MetaADEDB
Breath Sounds Abnormal ADReCS
Bronchopneumonia MetaADEDB
Bundle Branch Block Left MetaADEDB
Bundle Branch Block Right MetaADEDB
C-Reactive Protein Increased MetaADEDB
Caecitis ADReCS
Candidiasis ADReCS
Capillary Leak Syndrome ADReCS
Cardiac Decompensation MetaADEDB
Cardiac Disorder ADReCS
Cardiac Enlargement MetaADEDB
Cardiac Failure ADReCS
Cardiac Failure Acute MetaADEDB
Cardiac Failure Congestive ADReCS
Cardiac Ischemia MetaADEDB
Cardiac Tamponade MetaADEDB
Cardio-Respiratory Arrest MetaADEDB
Cardioactive Drug Level Increased MetaADEDB
Cardiomyopathy MetaADEDB
Cardiopulmonary Failure MetaADEDB
Cardiotoxicity MetaADEDB
Cardiovascular Insufficiency MetaADEDB
Cartilage Development Disorder MetaADEDB
Cataract MetaADEDB
Catheter Related Infection MetaADEDB
Catheter Site Pain MetaADEDB
Cell Death MetaADEDB
Cerebral Haemorrhage MetaADEDB
Cerebral Hypoperfusion MetaADEDB
Chest Pain ADReCS
Chest X-Ray Abnormal MetaADEDB
Chills ADReCS
Chlamydia Identification Test Positive MetaADEDB
Choking Sensation MetaADEDB
Circumstance Or Information Capable Of Leading To Medication Error MetaADEDB
Clonus MetaADEDB
Colitis Pseudomembranous MetaADEDB
Colpitis MetaADEDB
Coma ADReCS
Computerised Tomogram MetaADEDB
Concomitant Disease Aggravated MetaADEDB
Condition Aggravated MetaADEDB
Confabulation MetaADEDB
Confusional State ADReCS
Congenital Mitral Valve Incompetence MetaADEDB
Congenital Tricuspid Valve Incompetence MetaADEDB
Constipation ADReCS
Convulsion ADReCS
Cough ADReCS
Coughing Blood MetaADEDB
Crepitations ADReCS
Cryptogenic Organising Pneumonia MetaADEDB
Csf Protein MetaADEDB
Decreased Appetite ADReCS
Dehydration MetaADEDB
Demyelination MetaADEDB
Dental Care MetaADEDB
Dental Pain MetaADEDB
Depressed Level Of Consciousness MetaADEDB
Depression ADReCS
Dermatitis ADReCS
Dermatitis Bullous ADReCS
Dialysis MetaADEDB
Diarrhoea ADReCS
Diarrhoea Haemorrhagic ADReCS
Differential White Blood Cell Count Abnormal MetaADEDB
Difficulty In Walking MetaADEDB
Diffuse Alveolar Damage MetaADEDB
Disorder Lung MetaADEDB
Disseminated Intravascular Coagulation ADReCS
Disturbance In Attention MetaADEDB
Dizziness ADReCS
Drug Hypersensitivity ADReCS
Dry Eye ADReCS
Dry Mouth ADReCS
Dry Skin ADReCS
Dyspepsia ADReCS
Dysphagia ADReCS
Dyspnea Exertional MetaADEDB
Dyspnoea ADReCS
Dyspnoea Exacerbated MetaADEDB
Ear Disorder ADReCS
Ear Pain ADReCS
Ecchymosis ADReCS
Effusion ADReCS
Ejection Fraction Decreased MetaADEDB
Electrocardiogram Abnormal ADReCS
Electrocardiogram Qt Corrected Interval Prolonged MetaADEDB
Electrocardiogram Qt Prolonged ADReCS
Electrocardiogram Repolarisation Abnormality MetaADEDB
Electrocardiogram St Segment Elevation MetaADEDB
Electrocardiogram St-T Change MetaADEDB
Electrolyte Disorder MetaADEDB
Emphysema MetaADEDB
Enlarged Spleen MetaADEDB
Enteritis Infectious MetaADEDB
Enuresis ADReCS
Epistaxis ADReCS
Eruption MetaADEDB
Erythema ADReCS
Excess Potassium MetaADEDB
Extrapyramidal Disorder MetaADEDB
Extrasystoles ADReCS
Extrasystoles Ventricular MetaADEDB
Eye Irritation ADReCS
Eye Pain ADReCS
Eye Redness SIDER
Eye Rolling MetaADEDB
Eyelid Oedema ADReCS
Face Oedema ADReCS
Facial Palsy MetaADEDB
Faecal Incontinence ADReCS
Fatigue ADReCS
Febrile Bone Marrow Aplasia MetaADEDB
Febrile Neutropenia ADReCS
Feeling Abnormal ADReCS
Fibrin Degradation Products Increased MetaADEDB
Fibula Fracture MetaADEDB
Flank Pain MetaADEDB
Fluid Overload MetaADEDB
Flushing ADReCS
Fungal Disease MetaADEDB
Gamma-Glutamyltransferase Increased MetaADEDB
Gastrointestinal Bleed MetaADEDB
Gastrointestinal Disorder SIDER
Gastrointestinal Haemorrhage ADReCS
Gastrointestinal Obstruction MetaADEDB
Gastrointestinal Pain ADReCS
General Physical Condition MetaADEDB
Granulocytosis MetaADEDB
Granuloma MetaADEDB
Groin Abscess MetaADEDB
Haematemesis MetaADEDB
Haemodynamic Instability MetaADEDB
Haemoglobin ADReCS
Haemolysis MetaADEDB
Haemoptysis ADReCS
Haemorrhage ADReCS
Haemorrhagic Hepatic Cyst MetaADEDB
Head Titubation MetaADEDB
Headache ADReCS
Heart Rate Increased MetaADEDB
Hematoma Subdural MetaADEDB
Hepatic Enzyme MetaADEDB
Hepatic Function Abnormal MetaADEDB
Hepatosplenomegaly MetaADEDB
Herpes Nos SIDER
Herpes Simplex ADReCS
Herpes Virus Infection ADReCS
Herpes Zoster ADReCS
Hilar Lymphadenopathy MetaADEDB
Hyperglycaemia ADReCS
Hyperhidrosis ADReCS
Hyperkalaemia ADReCS
Hypersensitivity ADReCS
Hypertension ADReCS
Hypoaesthesia MetaADEDB
Hypoalbuminaemia ADReCS
Hypocalcaemia ADReCS
Hypoglycaemia ADReCS
Hypokalaemia ADReCS
Hypomagnesaemia ADReCS
Hyponatraemia ADReCS
Hypophosphataemia ADReCS
Hypoproteinaemia MetaADEDB
Hypotension ADReCS
Hypovolaemia MetaADEDB
Hypoxia ADReCS
Incontinence ADReCS
Increased Bronchial Secretion MetaADEDB
Increased Upper Airway Secretion MetaADEDB
Increased White Blood Cell Count MetaADEDB
Infection ADReCS
Infestation SIDER
Infestation Nos SIDER
Inflammation ADReCS
Injection Site Erythema ADReCS
Injection Site Oedema ADReCS
Injection Site Pain ADReCS
Insomnia ADReCS
Intention Tremor MetaADEDB
International Normalised Ratio Decreased MetaADEDB
Left Ventricular Hypertrophy MetaADEDB
Leucopenia MetaADEDB
Leukocytosis ADReCS
Leukopenia Neonatal MetaADEDB
Light Chain Analysis Increased MetaADEDB
Lipase Increased ADReCS
Livedo Reticularis MetaADEDB
Lower Gastrointestinal Haemorrhage MetaADEDB
Lung Consolidation MetaADEDB
Lung Edema MetaADEDB
Lung Infiltration ADReCS
Lymphadenopathy ADReCS
Malignant Neoplasm Progression MetaADEDB
Markedly Reduced Dietary Intake MetaADEDB
Mediastinal Disorder SIDER
Mental Disorder SIDER
Metal Poisoning MetaADEDB
Metastases To Central Nervous System MetaADEDB
Metastases To Pancreas MetaADEDB
Metrorrhagia ADReCS
Miosis MetaADEDB
Mouth Ulcer MetaADEDB
Movement Disorder MetaADEDB
Mucosal Inflammation ADReCS
Muscle Weakness MetaADEDB
Muscular Weakness ADReCS
Musculoskeletal Discomfort ADReCS
Myalgia ADReCS
Mycobacterial Infection MetaADEDB
Mycoplasma Serology MetaADEDB
Nasopharyngitis ADReCS
Nausea ADReCS
Neck Pain ADReCS
Neoplasia MetaADEDB
Neoplasm Malignant ADReCS
Nervous System Disorder SIDER
Neumonia MetaADEDB
Neuralgia ADReCS
Neuropathy ADReCS
Neuropathy Peripheral ADReCS
Neutropenia ADReCS
Neutropenic Sepsis MetaADEDB
Neutrophil Count Decreased MetaADEDB
Night Sweats ADReCS
Nodule Skin MetaADEDB
Nuclear Magnetic Resonance Imaging Brain Abnormal MetaADEDB
Obstructive Airways Disorder MetaADEDB
Ocular Hyperaemia ADReCS
Oedema ADReCS
Oliguria ADReCS
Oral Candidiasis ADReCS
Oral Mucosal Blistering MetaADEDB
Oral Soft Tissue Disorder MetaADEDB
Oropharyngeal Blistering ADReCS
Oropharyngeal Discomfort ADReCS
Oropharyngeal Pain ADReCS
Osteomyelitis Drainage MetaADEDB
Pain ADReCS
Pain In Extremity ADReCS
Painful Red Eyes SIDER
Pallor ADReCS
Palpitation MetaADEDB
Palpitations ADReCS
Pancreatitis MetaADEDB
Pancytopenia ADReCS
Paraesthesia ADReCS
Pco2 Decreased MetaADEDB
Pedal Pulse Absent MetaADEDB
Penile Oedema MetaADEDB
Pericardial Effusion MetaADEDB
Pericardial Haemorrhage MetaADEDB
Pericarditis MetaADEDB
Peripheral Sensory Neuropathy ADReCS
Personality Change MetaADEDB
Petechiae ADReCS
Phlebitis MetaADEDB
Pitting Oedema MetaADEDB
Platelet Count MetaADEDB
Pleural Disorder ADReCS
Pleural Effusion ADReCS
Pneumocystis Jiroveci Pneumonia MetaADEDB
Pneumonia ADReCS
Pneumonia Mycoplasmal MetaADEDB
Pneumonia Staphylococcal MetaADEDB
Pneumonia Viral MetaADEDB
Pneumothorax MetaADEDB
Po2 Decreased MetaADEDB
Postnasal Drip ADReCS
Postoperative Fever MetaADEDB
Protein Total Decreased MetaADEDB
Prothrombin Level Decreased MetaADEDB
Pruritus ADReCS
Pulmonary Cavitation MetaADEDB
Pulmonary Mass MetaADEDB
Pulmonary Oedema ADReCS
Pyrexia ADReCS
Rales ADReCS
Rash ADReCS
Red Blood Cell Abnormality MetaADEDB
Renal Failure ADReCS
Renal Impairment ADReCS
Respiratory Disorder MetaADEDB
Respiratory Distress ADReCS
Respiratory Rate Increased MetaADEDB
Respiratory Sounds Decreased SIDER
Respiratory Tract Congestion MetaADEDB
Respiratory Tract Infection ADReCS
Respiratory Tract Infection Fungal MetaADEDB
Retinoic Acid Syndrome ADReCS
Rhinorrhoea ADReCS
Rhonchi ADReCS
Rigors SIDER
Sepsis ADReCS
Septic Embolus MetaADEDB
Shoulder Pain MetaADEDB
Sinusitis ADReCS
Skin Exfoliation ADReCS
Skin Hyperpigmentation ADReCS
Skin Lesion ADReCS
Small Intestinal Haemorrhage MetaADEDB
Somnolence ADReCS
Spinal Column Stenosis MetaADEDB
Spinal Fracture MetaADEDB
Stomatitis ADReCS
Supraventricular Tachycardia MetaADEDB
Sweating SIDER
Sweating Increased SIDER
Tachycardia ADReCS
Tachycardia Ventricular MetaADEDB
Tachypnoea ADReCS
Tenderness ADReCS
Throat Sore SIDER
Thrombocytopenia ADReCS
Tibia Fracture MetaADEDB
Tinnitus ADReCS
Torsade De Pointes ADReCS
Transient Ischaemic Attack MetaADEDB
Treatment Noncompliance MetaADEDB
Tremor ADReCS
Upper Respiratory Tract Infection ADReCS
Upper-Airway Cough Syndrome ADReCS
Urethral Disorder SIDER
Urinary Tract Disorder SIDER
Urine Arsenic Increased MetaADEDB
Urticaria ADReCS
Vaginal Haemorrhage ADReCS
Ventricular Extrasystoles ADReCS
Ventricular Tachycardia ADReCS
Vertigo ADReCS
Vision Blurred ADReCS
Vomiting ADReCS
Weakness SIDER
Weight Decreased ADReCS
Weight Gain MetaADEDB
Weight Increased ADReCS
Wheezing ADReCS
Wound Drainage MetaADEDB

InAADR: Drug-Protein-ADRs database